Eris Lifesciences is currently trading at Rs. 741.35, up by 35.65 points or 5.05% from its previous closing of Rs. 705.70 on the BSE.
The scrip opened at Rs. 732.00 and has touched a high and low of Rs. 773.40 and Rs. 732.00 respectively. So far 7317 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 863.15 on 19-Oct-2021 and a 52 week low of Rs. 523.00 on 07-Dec-2020.
Last one week high and low of the scrip stood at Rs. 773.40 and Rs. 699.05 respectively. The current market cap of the company is Rs. 9591.07 crore.
The promoters holding in the company stood at 52.68% while Institutions and Non-Institutions held 23.54% and 23.78% respectively.
Eris Lifesciences has formed a joint venture with Mumbai-based MJ Biopharm to enter the insulin segment. Eris MJ Biopharm, the 70:30 joint venture (with Eris holding a 70 per cent stake), would primarily engage in marketing and distribution of human and analogue insulin including Aspart, Glargine and Lispro and GLP-1 agonists and potentially other biopharma products in India. MJ will be responsible for the development, manufacturing and supply of these products to the JV.
Eris Lifesciences is the only publicly listed Indian pharmaceutical company with a pure-play domestic branded formulations business model.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1814.70 |
Dr. Reddys Lab | 1327.15 |
Cipla | 1508.20 |
Lupin | 2149.25 |
Zydus Lifesciences | 984.40 |
View more.. |